NCT03300609View on ClinicalTrials.gov

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

October 3, 2019

Study Completion Date

October 3, 2019

Conditions
Colorectal AdenocarcinomaRAS Wild TypeStage III Colorectal Cancer AJCC v7Stage IIIA Colorectal Cancer AJCC v7Stage IIIB Colorectal Cancer AJCC v7Stage IIIC Colorectal Cancer AJCC v7Stage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7
Interventions
BIOLOGICAL

Panitumumab

Given IV

DRUG

Oxaliplatin

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Fluorouracil

Given IV

DRUG

Capecitabine

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Amgen

INDUSTRY

lead

University of Southern California

OTHER